Investors / United States / T1D Fund
T1D Fund
Venture capital · Boston, MA, United States · North America
The T1D Fund is a not-for-profit venture investment subsidiary of Breakthrough T1D (formerly JDRF) that invests in companies developing therapies for type 1 diabetes. It co-invests with venture capital firms and biopharma companies and reinvests all returns into new investments.
Invests inHealthcare & Biotech
In its own wordstype 1 diabetesbiotechtherapeuticscell therapyautoimmuneimpact investing
Your fit with T1D Fund
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsT1D Fund lists 30 checked portfolio companies on its own site and is named in 5 funding rounds, 1 of them as lead. Its most frequent entry is Series B, 75% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 77% of its companies are based in United States. It invests most often alongside ARCH Venture Partners, RA Capital and Sanofi Ventures.
Counts come from funding rounds that name T1D Fund, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not T1D Fund's whole history. Rounds on record name 5 companies; its own site lists 30. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundT1D Fund does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 25% |
| Series B | 75% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 2 | 1 |
| '26 | 3 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 66th | 29 companies |
| Recent activity | 76th | 3 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 84th | 14% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 78th | 5 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| ARCH Venture Partners | 5 |
| RA Capital | 3 |
| Sanofi Ventures | 3 |
| Altitude Life Science Ventures | 2 |
| Casdin Capital | 2 |
| F-Prime Capital | 2 |
| Narya | 2 |
| Novateur Ventures | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers2790%
- No longer answers00%
- Points to another company310%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with ARCH Venture Partners
Compare T1D Fund head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with T1D Fund| Date | Company | Stage |
|---|---|---|
| 7 Oct 2026 | Series B | |
| 18 Jun 2026 | Series B | |
| 8 Jan 2026 | Round | |
| 28 Oct 2025 | Series A Led | |
| 10 Sept 2025 | Series B |
Round details for T1D Fund
Amounts, full round histories and every co-investor in T1D Fund's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
30 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Adaxion Therapeutics is advancing biologics deimmunized with their ADAx platform to overcome immunogenicity limitations in biologic therapies | Healthcare & Biotech | Portfolio page | ||
| Aera Therapeutics develops delivery platforms for genetic medicines | Healthcare & Biotech | Portfolio page | ||
| Altrubio develops novel therapeutics for immunological diseases | Healthcare & Biotech | Portfolio page | ||
| Aspect Biosystems develops bioprinted tissue therapeutics to treat diseases | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Biolinq develops and manufactures a fully autonomous, needle-free glucose sensor | Healthcare & Biotech | Portfolio page | ||
| Caspian Therapeutics is advancing a portfolio of menin inhibitors as a treatment for diabetes and other chronic metabolic diseases. | Healthcare & Biotech | Portfolio page | ||
| Century Therapeutics develops cell therapies to treat autoimmune diseases and cancer. | Healthcare & Biotech | Jan 2026Round | Page + round | |
| COUR Pharma develops targeted therapies for autoimmune diseases | Healthcare & Biotech | Jun 2026Series B | Page + round | |
| Diasome Pharmaceuticals develops therapies for metabolic diseases, particularly diabetes, by targeting the liver with its Hepatocyte-Directed Vesicle platform. | Healthcare & Biotech | Portfolio page | ||
| DiogenX is a preclinical stage biotech company committed to discovering and developing innovative biologics as new therapeutics options for diabetic patients. | Healthcare & Biotech | Portfolio page | ||
| Egle Therapeutics develops precision medicines that modulate regulatory T cells to treat autoimmune diseases and cancer. | Healthcare & Biotech | Portfolio page | ||
| Eledon Pharmaceuticals develops immunosuppression therapies to protect transplanted organs and reduce the lifelong burden of immunosuppression | Healthcare & Biotech | Portfolio page | ||
| GentiBio is a clinical-stage company developing engineered Treg therapies to cure Type 1 diabetes and other autoimmune or acute inflammatory diseases | Healthcare & Biotech | Portfolio page | ||
| Immunocore develops immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Jaguar Gene Therapy accelerates breakthroughs in gene therapy for patients suffering from severe genetic diseases. | Healthcare & Biotech | Portfolio page | ||
| Kriya Therapeutics is building a new generation of durable medicines designed to be one-time treatments for chronic diseases | Healthcare & Biotech | Portfolio page | ||
| Kriya Therapeutics is developing durable medicines for chronic diseases | Healthcare & Biotech | Sept 2025Series B | Funding round | |
| Matchpoint Therapeutics is discovering precision small molecule medicines to transform the treatment of immune diseases. | Healthcare & Biotech | Oct 2026Series B | Page + round |
About this data
site last read 5 Nov 2026- Site
- t1dfund.org
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 10 Sept 2025
- Companies checked
- 30
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get T1D Fund's profile as data
Pull T1D Fund's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/t1dfund.org
# also
GET /v1/firms/t1dfund.org/portfolio
GET /v1/firms/t1dfund.org/coinvestors
GET /v1/firms/t1dfund.org/news